Position in PHVS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$14,068,146
+$10,536,896 QoQ
Shares Held
406,829
+225.5% QoQ
Ownership
0.579%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#33
of 124 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PHVS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Alyeska Investment Group, L.P. holds $989,063,778 across 83 Biotechnology names. PHVS ranks #18 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
659,279 | $123,469,771 | |
| 2 | IONS |
Ionis Pharmaceuticals Inc
|
1,417,916 | $112,426,559 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
889,298 | $109,010,148 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
|
697,692 | $42,112,689 | |
| 5 | MRNA |
Moderna, Inc.
|
560,819 | $39,274,154 | |
| 6 | KYMR |
Kymera Therapeutics, Inc.
|
276,455 | $31,701,094 | |
| 7 | LBRX |
Lb Pharmaceuticals Inc
|
863,947 | $28,039,399 | |
| 8 | PRAX |
Praxis Precision Medicines, Inc.
|
80,846 | $27,066,432 |
All Filings in PHVS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $14,068,146 | 406,829 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $3,531,250 | 125,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,468,750 | 125,000 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $3,118,750 | 125,000 | Shares | Sole | 2025-11-17 | |
| No filing history on record for this holder in this stock. | ||||||